|
gptkbp:instanceOf
|
Sleep disorder
|
|
gptkbp:alsoKnownAs
|
gptkb:narcolepsy_with_cataplexy
|
|
gptkbp:associatedWith
|
gptkb:HLA-DQB1*06:02_allele
|
|
gptkbp:cause
|
loss of hypocretin-producing neurons
|
|
gptkbp:complication
|
gptkb:depression
obesity
social impairment
|
|
gptkbp:diagnosedBy
|
gptkb:multiple_sleep_latency_test
polysomnography
|
|
gptkbp:differentialDiagnosis
|
obstructive sleep apnea
idiopathic hypersomnia
narcolepsy type 2
|
|
gptkbp:duration
|
lifelong
|
|
gptkbp:feature
|
low cerebrospinal fluid hypocretin-1
|
|
gptkbp:firstDescribed
|
19th century
|
|
gptkbp:frequency
|
1 in 2,000 people
|
|
gptkbp:gender
|
equal male and female prevalence
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
narcolepsy type 1
|
|
gptkbp:ICD-10_code
|
G47.41
|
|
gptkbp:OMIM
|
161400
|
|
gptkbp:onset
|
childhood
adolescence
|
|
gptkbp:parent
|
narcolepsy
|
|
gptkbp:prevalence
|
rare
|
|
gptkbp:prognosis
|
chronic
|
|
gptkbp:riskFactor
|
genetic predisposition
autoimmune response
|
|
gptkbp:symptom
|
gptkb:hypnagogic_hallucinations
excessive daytime sleepiness
sleep paralysis
cataplexy
fragmented nighttime sleep
|
|
gptkbp:treatment
|
gptkb:sodium_oxybate
gptkb:modafinil
antidepressants
stimulants
|
|
gptkbp:bfsParent
|
gptkb:HLA-DQB1*06:02_allele
gptkb:Narcolepsy_type_2
|
|
gptkbp:bfsLayer
|
8
|